Company intelligence / Profile preview
Replicate Bioscience
San Diego, California, United Statesreplicatebioscience.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Replicate Bioscience has demonstrated first-in-human data for its optimized srRNA rabies vaccine in a Phase I study showing safety and immunogenicity. The company reports robust preclinical progress across infectious disease, oncology, and autoimmune indications. Its platform enables high protein expression at low doses with durable effects compared to linear mRNA approaches.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- self-replicating RNA (srRNA)RNA therapeutics/vaccinesImmunotherapiesProtein expression platforms
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Exclusive technology license from Duke University for preventing drug-resistant cancer mutations.
Beyond the preview
Go deeper on Replicate Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Replicate Bioscience.